Home >
News >
#ESHCML2021: LATE BREAKING ABSTRACTS: DEADLINE JULY 31st
#ESHCML2021: LATE BREAKING ABSTRACTS: DEADLINE JULY 31st
July 09, 2021
23rd ANNUAL JOHN GOLDMAN CONFERENCE ON
CHRONIC MYELOID LEUKEMIA:
BIOLOGY AND THERAPY
October 7-10, 2021 - E-CONFERENCE
FREE REGISTRATION
Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger,
Olivier Hantschel, François-Xavier Mahon, Danilo Perrotti, Jerry Radich, Delphine Réa
Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
LATE BREAKING ABSTRACTS
DEADLINE: JULY 31st, 2021!
ABOUT THE CONFERENCE
In view of continuing COVID-19 related challenges, the 23rd Annual John Goldman Conference on CML will be held as a virtual event.
REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.
ABOUT THE PROGRAM:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The program will include:
- John Goldman Prize Lecture
- Janet Rowley Prize Lecture
- iCMLf Prize Lecture
- ESH John Goldman International Research Award presentations
- Keynote lectures
- Special lectures
- Oral communications selected from submitted abstracts
- Workshops for non-clinical scientists
- Meet-the-Expert Sessions
- Clinical and Biology manned poster walks
- Special Clinical Symposium 2021
PROGRAM HIGHLIGHTS
Friday October 8th, 2021: 17:50-19:50 CEST
WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
EPIGENETICS
Chairs: Ravi Bhatia (Birmingham), David Vetrie (Glasgow)
17:50-17:55 Introduction
Ravi Bhatia (Birmingham), David Vetrie (Glasgow)
17:55-18:20 Use of cutting-edge techniques
Greg Wang (Chapel Hill)
18:20-18:45 Use of chromatin conformation capture assays (3C/4C)
Michelle West (Brighton)
18:45-19:10 Multimodal single-cell analysis delineates the evolution of myeloid leukemia
Peter van Galen (Boston)
19:10-19:50 Live Interactive Discussion & Conclusion
Sunday October 10th, 2021: 11:00-13:00 CEST
WORKSHOP FOR NON-CLINICAL SCIENTISTS #2
SINGLE CELL ANALYSIS
Chairs: Mhairi Copland (Glasgow), Satu Mustjoki (Helsinki)
11:00-11:05 Introduction
Mhairi Copland (Glasgow), Satu Mustjoki (Finland)
11:05-11:30 Application of single cell technologies
Ana Cvejic (Cambridge)
11:30-11:55 Defining CML stem cells using single-cell genomics
Göran Karlsson (Lund)
11:55-12:20 Use of single cell technologies in the study of myeloproliferative neoplasms
Rebekka Schneider (Rotterdam)
12:20-13:00 Live Interactive Discussion & Conclusion
Educational Objectives:
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.
MORE INFORMATION
With the support of*:
Emerald E-Conference Partner
*********
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
